Author Affiliations: School of Nursing (Dr Chan, Ms Betancur, and Drs Hirschey, Anderson, and Bryant), Health Sciences Library (Ms Conklin), and Lineberger Comprehensive Cancer Center (Drs Hirschey, Foster, and Bryant), University of North Carolina at Chapel Hill; Department of Exercise Science, Elon University (Dr Piepmeier), North Carolina; and School of Nursing, University of Pittsburgh (Dr Bender), Pennsylvania.
Cancer Nurs. 2024;47(2):121-131. doi: 10.1097/NCC.0000000000001164. Epub 2022 Dec 11.
Chemotherapy is essential for treating acute myeloid leukemia (AML). Previous studies concluded that survivors of cancer who were treated with chemotherapy experience cognitive impairment. Therefore, it is important to understand cognitive function in survivors of AML.
The aim of this study was to explore distributions and correlates of cognitive function, and prediction of cognitive function on other outcomes in adults with AML who were treated with chemotherapy.
A health science librarian systematically searched PubMed, CINAHL, PsycINFO, and EMBASE databases. Two reviewers independently conducted the title, abstract, and full-text screening. Data were extracted and synthesized based on the aims of the review.
A total of 10 articles were included. Findings indicate that up to 62.2% of adults with AML experienced impaired cognitive function after starting chemotherapy. Three studies found cognitive function remained stable over time. Education and cytokines were potential correlates of cognitive function. Worse cognitive function may predict lower physical performance and higher mortality, although the results were inconsistent across studies.
Impaired cognitive function was observed in adults with AML who were treated with chemotherapy. However, no study used a validated subjective cognitive-function-specific patient-reported questionnaire, and previous studies focusing on cognitive function included relatively young samples. Hence, further research on cognitive function in older adults with AML is needed.
Because of the high prevalence of cognitive impairment identified, it is important to screen cognitive function in adults with AML who are planning to receive chemotherapy to intervene and provide support earlier.
化疗对于治疗急性髓系白血病（AML）至关重要。先前的研究得出结论，接受化疗的癌症幸存者会出现认知障碍。因此，了解 AML 幸存者的认知功能非常重要。
本研究旨在探讨接受化疗的 AML 成年患者认知功能的分布和相关因素，以及认知功能对其他结局的预测。
由一名健康科学图书管理员系统地检索了 PubMed、CINAHL、PsycINFO 和 EMBASE 数据库。两名审查员独立进行了标题、摘要和全文筛选。根据综述目的提取和综合数据。
共纳入 10 篇文章。研究结果表明，多达 62.2%的接受化疗的 AML 成年患者出现认知功能受损。有 3 项研究发现认知功能随时间保持稳定。教育和细胞因子可能是认知功能的潜在相关因素。较差的认知功能可能预示着较低的身体机能和较高的死亡率，尽管研究结果不一致。
接受化疗的 AML 成年患者存在认知功能受损。然而，没有研究使用经过验证的、针对特定认知功能的主观患者报告问卷，且先前关注认知功能的研究纳入的样本相对较年轻。因此，需要对老年 AML 患者的认知功能进行进一步研究。
鉴于确定的认知障碍高发率，在计划接受化疗的 AML 成年患者中筛查认知功能非常重要，以便及早进行干预和提供支持。
